MTOR and cervical cancer: Another therapeutic opportunity could be to reduce long non-coding RNA oncogenes such as gastric carcinoma proliferation enhancing transcript 1 (GHET1), which has been shown to activate both mTOR and Wnt/β-catenin pathways in cervical cancer [93].